← All trials
NCT04644484
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 23, 2020
- Primary completion
- May 30, 2021
- Completion date
- Dec 30, 2022
- First posted
- Nov 25, 2020
- Last posted
- Nov 25, 2020
- Enrollment
- 1000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Synermore Biologics Co., Ltd.Lead sponsor
- Government of ChinaCollaborator
- Clinchoice IncCollaborator
- Government of ChinaOverall official - principal investigator
- Government of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.